de Novo DLBCL

1 clinical trials · Condition

Record	Firm	Date
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (NCT01321541)	CTI BioPharma	2011-04-20

Every clearance here is in the API, with alerts when new ones post.